Novartis reported CHF27.65B in Current Liabilities for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Liabilities Change
Alcon AG ALC:SW 2.22B 31.63M
Amgen AMGN:US $ 12618M 268M
Artemis Alpha ATS:LN 537.4M 2.5M
AstraZeneca AZN:LN 1791796.84M 60282.28M
Bayer BAYN:GR € 33643M 2624M
Biogen BIIB:US $ 5018M 1071.4M
Bristol Myers Squibb BMY:US $ 20915M 1906M
Eli Lilly And LLY:US $ 15620.6M 2234.6M
Fresenius FRE:GR € 14300M 162M
Fresenius Medical Care FME:GR € 6877M 499.55M
Galapagos GLPG:NA € 550.72M 12.17M
Genmab GEN:DC DK 1944M 605M
Gilead Sciences GILD:US $ 9220M 662M
GlaxoSmithKline GSK:LN 3783500M 1355700M
Hikma Pharmaceutical HIK:LN 82.96B 7.86B
Lonza Group LONN:SW 2.63B 256M
Merck MRK:GR € 9718M 489M
Novartis NOVN:VX SF 27646M 2161M
Novartis NVS:US $ 27646M 2161M
Orion ORNBV:FH € 235.9M 199.9M
Recordati REC:IM € 851.2M 126.18M
Regeneron Pharmaceuticals REGN:US $ 3033.9M 26.3M